Allogene Therapeutics (ALLO) Return on Sales (2021 - 2024)
Historic Return on Sales for Allogene Therapeutics (ALLO) over the last 4 years, with Q4 2024 value amounting to 11510.32%.
- Allogene Therapeutics' Return on Sales fell 77558400.0% to 11510.32% in Q4 2024 from the same period last year, while for Dec 2024 it was 11510.32%, marking a year-over-year decrease of 82531600.0%. This contributed to the annual value of 11708.64% for FY2024, which is 82637400.0% down from last year.
- Allogene Therapeutics' Return on Sales amounted to 11510.32% in Q4 2024, which was down 77558400.0% from 6384.35% recorded in Q3 2024.
- Allogene Therapeutics' Return on Sales' 5-year high stood at 0.03% during Q4 2021, with a 5-year trough of 11510.32% in Q4 2024.
- For the 4-year period, Allogene Therapeutics' Return on Sales averaged around 3186.92%, with its median value being 2965.59% (2022).
- In the last 5 years, Allogene Therapeutics' Return on Sales surged by 4374400bps in 2023 and then plummeted by -77558400bps in 2024.
- Allogene Therapeutics' Return on Sales (Quarter) stood at 0.03% in 2021, then crashed by -14392819bps to 3601.46% in 2022, then decreased by -4bps to 3754.48% in 2023, then plummeted by -207bps to 11510.32% in 2024.
- Its Return on Sales was 11510.32% in Q4 2024, compared to 6384.35% in Q3 2024 and 4094.6% in Q2 2024.